Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 126

Sort by

Sort Order Select

Journal Articles

TBI-ATG based conditioning regimen is a promising approach for adult patients with refractory and relapsed peripheral T cell lymphoma undergoing allogeneic peripheral blood stem cell transplantation

Chuxian Zhao, Daolin Wei, Huixia Liu, Ying Jiang, Shan Shao, Chun Wang, JUN Zhu

Blood (2025) 146 (Supplement 1): 4190.

https://doi.org/10.1182/blood-2025-4190

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Blood (2025) 146 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2025-3587

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Blood (2025) 146 (Supplement 1): 886.

https://doi.org/10.1182/blood-2025-886

Published: 2025

Journal Articles

Daratumumab and venetoclax-based combined regimen for relapsed/refractory T-lymphoblastic leukemia/lymphoma

Shan Shao, Chuxian Zhao, Huixia Liu, Chun Wang, JUN Zhu, Daolin Wei, Ying Jiang

Blood (2025) 146 (Supplement 1): 1568.

https://doi.org/10.1182/blood-2025-1568

Published: 2025

Journal Articles

The prospect of high-dose vitamin c in improving early survival in patients with hemophagocytic lymphohistiocytosis

Jiayi Ren, Wu Shishuang, Kai Qing, Jiong Hu, JUN Zhu, Yingying WANG, Ying-Li Wu, Kai Xue

Blood (2025) 146 (Supplement 1): 6550.

https://doi.org/10.1182/blood-2025-6550

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 3896.

https://doi.org/10.1182/blood-2025-3896

Published: 2025

Journal Articles

SL0439: A structure-tuned bispecific nanobody CAR-T cells targeting BCMA/GPRC5D for relapsed/refractory multiple myeloma with extramedullary disease

Su Li, JUN Zhu, Chengwei Jin, Wei Liu, Yan Zhao, Jingjing Wang, Chun Wang, Jian Hou, Jing PAN

Blood (2025) 146 (Supplement 1): 4146.

https://doi.org/10.1182/blood-2025-4146

Published: 2025

Journal Articles

Construction of a prognostic model for new diffuse large B-cell lymphoma and research on risk factors for secondary central nervous system infiltration

Shuling Hou, juya cui, Tao Wang, Jun Zhu

Blood (2025) 146 (Supplement 1): 5438.

https://doi.org/10.1182/blood-2025-5438

Published: 2025

Journal Articles

Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma (MCL) after receiving covalent bruton tyrosine kinase inhibitors (cBTKi) in China

Ningjing Lin, Yuqin Song, Xue Zhang, Guangdong Xie, Xiao Ma, Jun Zhu

Blood (2025) 146 (Supplement 1): 2704.

https://doi.org/10.1182/blood-2025-2704

Published: 2025

Journal Articles

Safety and Preliminary Efficacy of F0002, an Anti-CD30 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-1 or PD-L1 Therapy: Results from F0002-101 Phase 1 Study

Yuqin Song, Qingsong Yin, Zhiming Li, Jingye Meng, Yan Yan, Mengli Zhou, Wenyi Sun, Kezhen Liu, Jun Zhu

Blood (2024) 144 (Supplement 1): 1674.

https://doi.org/10.1182/blood-2024-193938

Published: 2024

Journal Articles

CD93 + Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity

Hui Yu, Yixin Qian, Weiping Liu, Lan Mi, Yun Huang, Rui Peng, Jiaowu Cao, Dingyao Hu, Jun Zhu, Yuqin Song, Mi Deng

Blood (2024) 144 (Supplement 1): 960.

https://doi.org/10.1182/blood-2024-201309

Published: 2024

Journal Articles

Linperlisib Combined with CHOP Regimen Followed By Autologous Hematopoietic Stem Cell Transplantation and Linperlisib Monotherapy Maintenance for Newly Diagnosed Nodal T-Follicular Helper Cell Lymphoma Patients: A Phase II Trial

Weiping Liu, Yao Liu, Zengjun Li, Shujuan Wen, Zhihua Zhang, Liqun Zou, Ming Jiang, Liping Dou, Ou Bai, Jie Yu, Yue Wang, Jie Chen, Yuqin Song, Jun Zhu

Blood (2024) 144 (Supplement 1): 6389.

https://doi.org/10.1182/blood-2024-199929

Published: 2024

Journal Articles

Safety and Efficacy of Iruplinalkib for Patients with Relapsed or Refractory (r/r) ALK+ Lymphoma: A Phase II Trial

Yue Wang, Fang Wei, Wanli Wang, Linjun Zhao, Jie Chen, Yuqin Song, Jun Zhu, Weiping Liu

Blood (2024) 144 (Supplement 1): 6386.

https://doi.org/10.1182/blood-2024-207002

Published: 2024

Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood (2024) 144 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2024-194572

Published: 2024

Journal Articles

Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

Lijuan Deng, Tianheng He, Yongjing Tang, Lan Mi, Changyu Lu, Hanxiao Liu, Shupeng Zhong, Jin Chai, Jun Luo, Liling Zhang, Shujuan Wen, Xiaopei Wang, Jun Zhu, Yuqin Song

Blood (2024) 144 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2024-209021

Published: 2024

Journal Articles

Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma

Jie Chen, Linjun Zhao, Chongyang Wu, Haifeng Yu, Zhenling Li, Lihong Liu, Da Gao, Ying Sun, Xiaolei Wei, Yuanbin Wu, Yue Wang, Yuqin Song, Jun Zhu, Weiping Liu

Blood (2024) 144 (Supplement 1): 1686.

https://doi.org/10.1182/blood-2024-207412

Published: 2024

Journal Articles

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Ningjing Lin, Tingting Du, Hui Zhou, Yajun Li, Liang Wang, Xiaomeng Dong, Haochuan Zheng, Jingtao Lu, Mi Tang, Jihua Wu, Wei Zhu, Yuqin Song, Jun Zhu

Blood (2024) 144 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2024-206674

Published: 2024

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Journal Articles

Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Lijuan Deng, Yanyan Liu, Ningjing Lin, Zhihua Yao, Jiuyang Zhang, Wei Meng, Qiying Lu, Wenzhi Tian, Jun Zhu, Yuqin Song

Blood (2024) 144 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2024-200539

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

TBI-ATG based conditioning regimen is a promising approach for adult patients with refractory and relapsed peripheral T cell lymphoma undergoing allogeneic peripheral blood stem cell transplantation

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Daratumumab and venetoclax-based combined regimen for relapsed/refractory T-lymphoblastic leukemia/lymphoma

The prospect of high-dose vitamin c in improving early survival in patients with hemophagocytic lymphohistiocytosis

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

SL0439: A structure-tuned bispecific nanobody CAR-T cells targeting BCMA/GPRC5D for relapsed/refractory multiple myeloma with extramedullary disease

Construction of a prognostic model for new diffuse large B-cell lymphoma and research on risk factors for secondary central nervous system infiltration

Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma (MCL) after receiving covalent bruton tyrosine kinase inhibitors (cBTKi) in China

Safety and Preliminary Efficacy of F0002, an Anti-CD30 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-1 or PD-L1 Therapy: Results from F0002-101 Phase 1 Study

CD93 + Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity

Linperlisib Combined with CHOP Regimen Followed By Autologous Hematopoietic Stem Cell Transplantation and Linperlisib Monotherapy Maintenance for Newly Diagnosed Nodal T-Follicular Helper Cell Lymphoma Patients: A Phase II Trial

Safety and Efficacy of Iruplinalkib for Patients with Relapsed or Refractory (r/r) ALK+ Lymphoma: A Phase II Trial

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only